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Abstract
Name:  M.B.Ch.B (University of Bagdad) Haifa Kathrin Al-Ali 
Title:               The impact of the age of HLA-identical siblings on mobilization and 
collection of PBSCs for allogeneic hematopoietic cell transplantation 
                        University of Leipzig, Dissertation 
                        P. 33, Ref. 40, Original publication 7 pages (12961302). 
Through the recruitment of immunologic mechanisms, allogeneic hematopoeitic cell 
transplantation (HCT) has been establiched as a curative treatment for various 
hematologic diseases. The most convenient source to obtain hematopoietic 
progenitor cells are peripheral blood stem cells (PBSCs) which are harvested from 
the donor via leukapheresis after mobilization with granulocyte-colony stimulating 
factors. With the introduction of reduced intensity condition (RIC), the curative 
potential of allogeneic HCT became accessible to older and/or frail patients otherwise 
ineligible for HCT. However, new challenges arise as the increasing age of patients is 
inevitably accompanied by a comparable increase in the age of donors. Safety 
considerations of collecting PBSCs might attain new dimensions. Data to potential 
risks in elderly donors are lacking. Moreover, the impact of donors age on the 
feasibility of PBSCs collection and on the quality of the harvest in terms of stem cells 
(CD34+) and natural killer (NK)-cells has not been studied. It is also unknown 
whether PBSCs obtained from donors above 50 years would negatively influence 
engraftment or the incidence of graft-versus-host disease (GVHD) in the recipient. 
These questions were explored in a retrospective study including 167 recipients of an 
allogeneic HCT (52.7% after RIC) from a matched related sibling. Median donors 
age was 47 years [67 (40%) donors were > 50 years including 34 donors > 60 years]. 
Safety of mobilization and leukapheresis was age independent. Adequate PBSCs 
were collected from all donors though a higher CD34+-cell count was seen in donors 
< 50 years (p<0.0005), whereas harvests from donors > 60 years contained a higher 
NK-cell count (p=0.003). Engraftment in the recipient occurred after a median of 12 
days and was not affected by an advanced donor age. Similarly, a higher incidence 
of GVHD was not seen in recipients of harvests from older donors. For the first time, 
we show that donors age, even beyond 60 years, does not preclude successful 
collection of PBSCs from siblings, does not jeopardize the short-term safety of the 
donor, and is not associated with deleterious sequels for the recipient in terms of 
engraftment or GVHD. As NK-cells have been implicated in the suppression of 
GVHD, and the mediation of a graft versus leukemia effect, the impact of the higher 
number of NK-cells in harvests from elderly donors on relapse of hematologic 
malignancies in the recipient warrants further studies.   
Abbreviations 
actR NK-cell activating receptor 
PBSC Peripheral blood stem cell 
BMT Bone marrow Transplantation 
G-CSF Granulocyte-colony stimulating factor 
GVHD Graft versus host disease 
GVL Graft-versus leukemia 
GVT Graft versus tumor 
HCT Hematopoietic cell transplantation 
HLA Human leukocyte antigen 
HPC Hematopoietic progenitor cells 
KIR Killer Ig-like receptor 
mHag Minor histocompatibility antigen 
MHC Major histocompatibility complex 
MRD Matched related donor 
MUD Matched unrelated donor 
NK-cells Natural killer cells 
RIC Reduced intensity conditioning 
TBI Total body irradiation 
TRM Treatment-related mortality 
UC Umilical cord 
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Introduction
Bone marrow transplantaion (BMT) was pioneered by E. Donnall Thomas in the 
1950s. He and his team showed that bone marrow cells infused intravenously could 
repopulate the bone marrow and produce new blood cells.[1] More precisely, BMT 
should be termed hematopoeitic cell transplantation (HCT) or hematopoeitic stem cell 
transplantation as peripheral blood stem cells (PBSC) or umbilical cord blood (UC) 
have emerged as further sources of procurement of hematopoietic progenitor cells 
(HPCs) used in HCT in addition to the traditional bone marrow.[2;3]  
Nowadays, HCT is an established treatment option for various malignant and non-
malignant hematologic diseases such as lymphoproliferative disorders, acute and 
leukemias, bone marrow failure, and hemoglobinopathies.[2;4] Further progress 
made over the last decades, allowed its use to expand beyond hematologic 
disorderes, such as for autoimmune diseases.[5] Worldwied, a total of 146,808 
transplants were reported over a 3-years period from 2006 to 2008. Of these, 55% 
were autologous and 45% were allogeneic.[2]  Overall, HCT offers a chance for cure 
or long-term remission in patients with different malignant and non-malignant 
hemtologic and non-hematologic diseases. However, outcome after HCT in terms of 
survival, disease-free survival, relapse incidence, and treatment-related mortality 
(TRM) varies widely and is dependent on a variety of closely interrelated factors such 
as the underlying disease [the diagnosis, the remission status, the cytogenetic and/or 
molecular risk profiles], the patient [the age, the performance status, and the 
presence of comorbidities], and the procedure itself [the type of HCT (autologous 
versus allogeneic), the source of HPCs (bone marrow versus PBSCs versus UC 
blood), the conditioning regimen used (myeloablative versus non-myeloablative), the 
experience of the unit conducting the transplantation, and the occurrence of 
transplantation-related complications]. Moreover, in the setting of allogeneic HCT, 
donor-related issues such as the availabiliy of a donor, the level of matching between 
donor and recipient, and the source of HPCs, are additional aspects that must be 
accounted for because of their significant impact on outcome after HCT.  
In the introductory part, the main aspects of HCT will be first reviewed to introduce 
the background of the publication under consideration in this dissertation. With this 
review, the inevitable interaction of the different transplant-related facets whith each 
other is highlighted. Subsequently, the rationales and the objectives of the work done 
at the University Hospital of Leipzig are presented. 
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1. Hematopoietic progenitor cells (HPCs) 
Stem cells are undifferentiated cells with the capacity to divide indefinitely, to self-
renew and to generate a functional progeny of highly specialized cells. In humans, 
HPCs are found in UC blood and post-natally in the bone marrow. In a well-defined 
irreversible path of progression, HPCs give rise to terminally differentiated myeloid 
(monocytes/macrophages, neutrophils, basophils, eosinophils, erythrocytes, and 
platelets), as well as lymphoid cell types (T-, B-, and natural killer (NK)-cells). HPCs 
can be phenotypically characterized by flowcytometry using monoclonal antibodies 
recognizing cell surface antigens. The most primitive HPC is a "Lin-" cell as it is 
negative for markers used to detect lineage commitment such as CD13/CD33 for 
myeloid-, CD71 for erythroid-, CD19 for B-, CD3 for T-, CD56 for NK-, and CD61 for 
megakaryocytic-cells. Further, it expresses CD34, CD133, and c-kit (the receptor for 
stem cell factor) and lacks CD38 cell surface antigens.[6-7]  
1.1. Sources of hematopoietic progenitor cells (HPCs)  
Currently, there are three possibilities to procure HPCs: bone marrow, peripheral 
blood and UC blood. These three sources result in comparable clinical results. 
Traditionally, HPCs were collected from the bone marrow under general anesthesia. 
This modality usually yields a limited number of HPCs.[8] UC blood cells could easily 
be collected and cryopreserved at birth, have a low risk of transmissible disease, and 
could be used in related or unrelated HLA matched and mismatched allogeneic 
transplants. A major limitation is the low number of HPCs available due to the small 
quantity of blood obtained from an UC. Therefore, this source of HPC is mainly used 
in children. The use of two cord blood units from different donors allows UC 
transplants to be used in adults.[3;9]  
Nowadays, granulocyte-colony stimulating factors (G-CSF) mobilized PBSCs which 
are subsequently collected peripherallly via leukapheresis are the most common 
source of HPCs applied in autologous as well as allogeneic HCT. G-CSF causes the 
proliferation of neutrophils and the release of proteases which degrade the proteins 
that anchor stem cells to the marrow stroma and together with protease-independent 
mechanisms free the cells to enter the circulation. Collection is easy, does not 
require general anasthesia, and usually yields a high number of HPCs. [2;8;10] 
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2. Types of HCT
2.1 Autologous HCT 
HCT is considered to be autologous when the patient's own HPCs are re-infused 
after inducing bone marrow ablation by high dose chemotherapy with or without 
radiotherapy to eradicate the diseased cell population. Simply, autologous HCT could 
be considered as a myeloablative therapy with stem cell support. A prerequisite to 
perform an autologous HCT is the availability of previously collected and 
cryopreserved HPCs from the patient himself. Because this form of transplantation is 
associated with a low risk of TRM, it has been established as an important treatment 
modality for different disorders particularly lymphoproliferative malignant diseases 
such as multiple myeloma and lympphoma.[11-12]  
On the other hand, this low TRM is counterbalanced by a high relapse rate in other 
malignant diseases such as acute leukemia which consequently limited its utility as 
an effective post-remission therapy in these disorders.[13]  
2.2 Allogeneic HCT 
HCT is allogeneic when the patient is not the source of the HPCs. Accordingly, the 
patient becomes a recipient of HPCs collected from another individual, the so called 
donor. It is well-known that malignant stem cells could repair DNA efficiently, resist 
apoptosis, excrete toxic drugs by means of ATP-binding transporters, and are 
quiescent. These attributes, make them less sensitive to chemotherapy than 
proliferating tumor cells. Some malignant stem cells survive even lethal doses of 
total-body irradiation (TBI) and high-dose chemotherapy usually applied in 
preparation for autologous HCT which ultimately leads to relapse of the original 
disease.[14]  
However, such malignant stem cells may be eliminated by immunologically active 
donor cells. This effect has been initially exploited in patients relapsing after 
allogeneic HCT. Without any further cytotoxic therapy, complete molecular 
remissions were induced by transfusing donor lymphocytes.[15-16] This compelling 
phenomenon is now known as the graft versus tumor (GVT) or graft versus leukemia 
(GVL) effect and is mediated by donor T-lymphocytes recognizing disease specific 
antigens in the recipient. Hence, allogeneic HCT emerged as a form of 
immunotherapy with a potent curative potential. 
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3. Immunogenetics of allogeneic HCT 
The human leukocyte antigen (HLA) system with its genetic complexity, is the major 
barrier to allogeneic HCT.[17] However, it is now well-appreciated that additional 
factors such as the minor histocompatibility antigens (mHag), and NK-cells do also 
play a substantial role in the immunogentics of allogeneic HCT.[18-21] 
3.1 The human leukocyte antigen (HLA) system  
Tissue compatibility is determined by genes of the major histocompatibility complex 
(MHC) which are clustered on the short arm of chromosome 6. In humans, this is 
known as the HLA system. HLA genes involved in the immune response fall into two 
classes. Class I genes which are expressed by most somatic cells and class II genes 
which are expressed by immune cells including B-, activated T-, dendritic-, and 
thymic epithelial-cells as well as by macrophages. Class I and class II molecules 
form complexes with peptides derived from endogenous and exogenous proteins 
respectively and present these peptides to T-cells, a process that initiates the 
adaptive immune response.[22]  
If major histocompatibility antigens of the donor are incompatible with those of the 
recipient, vigorous T-cell responses occur after allogeneic HCT which lead to serious 
and even lethal immune reactions in the recipient, known as the graft versus host 
disease (GVHD).[23-24] Thus in the allogeneic HCT setting, HLA typing is mandatory 
for the identification of a matched donor.[17] 
The accreditation program for the histocompatibility laboratories set up by the 
European Federation for Immunogenetics has defined minimal criteria for HLA typing 
in related and unrelated HCT.[25] The ideal donor is an HLA genotypically matched 
sibling whom is referred to as a matched related donor (MRD). HLA-A, -B, and DR by 
low resolution typing (serology or 2-digit DNA typing) is able to determine the 
paternal and maternal haplotypes in both patient and sibling.This simple ABDR 
typing usually can confirm identity for the whole set of HLA genes, i.e a 12/12 match. 
In contrast, high resolution molecular HLA typing to identify matches at allele-level is 
required to identify a matched unrelated donor (MUD). The gold standard comprises 
the analysis of HLA-A, -B, -C, -DRB1, and -DQB1 loci. If both patient and potential 
donor share the same 5 alleles on both haplotypes, then this is referred to as a 10/10 
match. High resolution HLA typing has been shown to improve the outcome after 
allogeneic transplant in the setting of a MUD.[26] 
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3.2. Minor histocompatibility antigens (mHags) 
Even so-called "perfect matches" may have mismatched minor alleles that contribute 
to GVHD. This is initiated by donor T-cells recognising mHags. These mHags are 
distinct from the MCH, are single peptides derived from polymorphic intracellular 
proteins, are coded by autosomal or Y chromosome genes, are presented by a small 
fraction of HLA molecules, and typically initiate weaker responses than the major 
antigens do.[18] 
For instance, minor antigens encoded by genes on the Y chromosome account for 
the higher incidence of GVHD and the lower rate of relapse of the underlying disease 
among male recipients of marrow transplants from female donors than among male 
recipients of transplants from male donors.[27-28] 
3.3 Natural-killer cells (NK-cells) 
NK-cells which are phenotypically characterized by flowcytometry as being CD3-
/CD56 +-cells, are the first lymphocyte subset to reconstitute the peripheral blood after 
allogeneic HCT.[29] NK-cells. are innate effectors and can rapidly produce cytokines 
and mediate cytotoxicity in response to NK-cell activating receptor (actR) ligands 
expressed on infected or transformed cells [19] A potent GVL effect might be induced 
after allogeneic HCT due to the fact that leukemic cells sometimes express various 
ligands recognized by NK-cell actRs.[20]  
Moreover, NK-cell activation is balanced by inhibitory signals delivered by the 
interaction between Killer Ig-like receptors (KIRs) and HLA class I molecules. Even in 
the setting of allogeneic HCT from a MRD, patients frequently lack an HLA ligand for 
the donor-inhibitory KIR. This leads to a NK-cell alloreactivity which has been shown 
to improve outcome after HCT in patients with myeloid malignancies.[21]  
4. Conditioning regimens prior to HCT  
4.1 Myeloablative conditioning  
The objectives of myeloablative preparation prior to HCT is to eradicate the disease 
clone and, in the case of allogeneic HCT, to induce immunosuppression that permits 
homing and engraftment of HPCs. Further, the conditioning regimen can augment 
the antitumor immune response by causing a breakdown of tumor cells, which results 
in a flood of tumor antigens into antigen-presenting cells.[30]  
Since the 1980s, fractionated TBI combined with high-dose cyclophosphamide has 
been used as a standard conditioning regimen worldwide. TBI is myeloablative and 
10 
immunosuppressive, is not associated with crossresistance to chemotherapy, and 
reaches sites that are not affected by chemotherapy. Fractionating the dose of TBI is 
effective in minimizing the toxicity of irradiation.[31] Yet, radiation-free regimens with 
high-dose chemotherapy alone such as busulfan combined with cyclophosphamide 
have also been developed as alternative preparative regimens to reduce the toxicity 
associated with TBI and to overcome the often encountered inaccessibility to 
radiation facilities.[32] 
For allogeneic HCT, the toxicity of myeloablative conditioning regimens increases 
with age, particularly after the age of 50 years which limited the availability of this 
form of immunotherapy to younger patients. 
4.2 Reduced intensity conditioning (RIC) 
The appreciation and understanding of the biology of the potent immunologic 
mediated GVL effect following allogeneic HCT which was discused previously under 
section 2.2, led to the development of the primarily immunosuppressive rather than 
myeloablative reduced-intensity preparative regimens in the late 1990s.[33] Thus, the 
principle of RIC HCT is not to destroy the host hematopoiesis nor to eradicate the 
tumor by cytotoxic therapies (myeloablation) but via immune mediated effects 
through the GVL potential of the transplant (immunoablation).  
The low toxicity of the various RIC strategies allowed the extension of the curative 
potential of allogeneic HCT to older patients as well as to recipients with 
comorbidities for whom myeloablative conditioning.was not possible.  
However, the low mortality rate associated with RIC may be offset by a high relapse 
rate of the underlying disease.[34] Nevertheless, allogeneic HCT after RIC is now an 
established transplant strategy particularly for elderly patients.  
5. Complications after HCT 
In spite of the introduction of RIC for allogeneic HCT and the hudge improvement 
made in supportive care measures, HCT remains a procedure with many early and 
late complications which might cause relevant treatment related morbidities and 
mortalities. Infections, and in the case of allogeneic HCT, GVHD are the two main 
complications seen. In fact, the main reason of death after HCT is TRM which 
accounts for 70% of fatalities encountered after HCT and not relapse of the 
underlying malignant disease.[35]   
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5.1 Infections 
Transplantation-related infections arise from the toxicity of the conditioning regimens, 
the central vein catheters, neutropenia, and immunodeficiency.  
The improvement in supportive care in addition to the development of efficient 
diagnostic techniques and anti-infectious agents, allow the establishment of prompt 
prophylactic as well as therapeutic measures to prevent and treat infections effectivly 
after HCT. In fact, death due to infections has been reduced significantly over time. 
Unfortunately, serious and even fatal infections are still seen. In a large survey of 
patients transplanted from an HLA-identical sibling, fatal infections were reported in 
4.1% of the recipients and were the major cause of death in 10% of the patients who 
ultimately died after HCT. Infections were mainly becterial in 36% of recipients. This 
was followed by viral, fungal, and parasitic infections in 31%, 28%, and 5% of 
patients respectively. Typically, serious infections are seen early after HCT with a 
median of 3 months following transplantation. Nevertheless, it must be remembered 
that fatal infections are possible even after one year after HCT.[35] 
5.2 Graft-versus-host disease (GVHD) 
In contrast to other organ transplantation, allogeneic HCT is the only transplant 
procedure in which the transplanted cells must accept the body of the recipient rather 
than the body accepting the new cells. GVHD which could be acute and/or chronic is 
mediated by donor T-cells which react to foreign peptides presented on the MHC of 
the host. Conditioning causes a severe inflammatory response prior to HCT. Tissues 
where there is constant antigen presentation such as lymph nodes and gut-
associated lymphoid tissue fuel the subsequent allogeneic responses by priming 
donor T cells, which then migrate to other organs and cause damage.[23-24] The 
liver, skin, intestinal tract, and lymphohematopoietic system are the major targets of 
GVHD. The profound immunodeficiency associated with GVHD is mainly due to loss 
of self-tolerance.[36] This is further accentuated by the immunosuppressive agents 
required for the treatment of GVHD such as corticosteroids. The risk of GVHD 
increases with increasing recipient and donor age, if PBSCs were the source of 
HPCs, or an unrelated donor was chosen.[37] GVHD remains the major cause of 
TRM and morbidity following allogeneic HCT. In contrast to infections, the incidence 
of GVHD has not been reduced over time.[35] 
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6. Rationales and objectives of the published work
From the previous discussion, it becomes evident that outcome after HCT including 
treatment-related morbidity and/or mortality is the end result of a complex interaction 
of well-studied disease-, patient-, and treatment-related variables. With the 
introduction of RIC, the curative potential of allogeneic HCT became accessible to 
older and/or frail patients otherwise ineligible for HCT. However, this raises new 
challenges as the increasing age of patients is inevitably accompanied by a 
comparable increase in the age and/or comorbidities of potential sibling donors. 
Worldwide, PBSCs which are harvested via leukapheresis after G-CSF mobilization 
are the most commonly used source to obtain HPCs for allogeneic HCT.[2] This 
approach is considered to be convenient and the risk for the donor minimal. 
Nevertheless, severe adverse events such as splenic rupture after G-CSF, and even 
death have been reported.[38-40] With the increasing age of potential sibling donors, 
safety issuses under G-CSF mobilization of HPCs and apheresis of PBSCs might 
attain new dimensions. Data to potential risks in elderly sibling donors are actually 
lacking. Moreover, the possible impact of the age of a MRD on mobilization, 
apheresis of PBSCs, and the number of CD34+- and NK-cells in the harvest has not 
been studied. Further, in the pre-RIC era, donor age and PBSCs have been 
associated with an increased risk of GVHD in the recipient.[37]. However, it is not 
known whether PBSCs obtained from donors above 50 or even 60 years would 
negatively influence engraftment or the incidence of GVHD in the recipient. 
Thus, we conducted a a large retrospective study including 167 patients who 
received an allogeneic HCT from a MRD with 40% of the donors being > 50 years of 
age at the University Hospital of Leipzig to explore the impact of this specific donor-
related variable, namely age, on the donor's own safety, on the feasibility of PBSC 
harvesting, and the quality of the transplant obtained in terms of stem cells (CD34+-
cells) and NK-cells. We also analyzed the influence of donor's age on subsequent 
engraftment in the recipient and the incidence of GVHD.  
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The impact of the age of HLA-identical siblings on mobilization and
collection of PBSCs for allogeneic hematopoietic cell transplantation
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With the increasing age of patients undergoing allogeneic
hematopoietic cell transplantation (HCT), the age of matched
related sibling donors (MRDs) is expected to increase.
Donor safety and the impact of donors’ age on mobiliza-
tion, collection of peripheral hematopoietic progenitor
cells (HPCs), subsequent engraftment and the incidence
of GVHD were retrospectively analyzed. A total of 167
patients received HCT from an MRD. Median donors’
age was 48 years (67 (40%) donors were X50 years
including 34 donors X60 years). Side effects under
mobilization and apheresis were age independent. Grafts
from donors o50 years contained more CD34þ cells
(median 9 106/kg recipient’s body weight (RBW))
compared with older donors (median 5.9 106/kg RBW)
(Po0.0005), whereas harvests from donors X60 years
contained more natural killer (NK) cells (P¼ 0.003).
Engraftment occurred at a median of 12 days after HCT
irrespective of donors’ age. Increasing age of MRD did
not preclude successful mobilization, collection of HPC
and engraftment. In the context of more NK cells in grafts
from elderly donors, the impact of donors’ age on outcome
after HCT warrants further studies. Although short-term
toxicities of apheresis were not increased with increasing
age, long-term donor safety remains an important issue.
Bone Marrow Transplantation (2011) 46, 1296–1302;
doi:10.1038/bmt.2010.310; published online 6 December 2010
Keywords: stem cell donor; elderly; graft; allogeneic
HCT; NK cells
Introduction
Of the three possibilities of procurement of hematopoietic
progenitor cells (HPCs), namely BM, granulocyte colony-
stimulating factor mobilized peripheral blood and cord
blood; peripheral blood is the predominant source of HPC
in Europe.1 Harvesting HPC is feasible, convenient and the
risk for the donor is generally considered minimal.2–5
If available, an HLA-identical sibling is usually the source
of HPC for patients requiring an allogeneic hematopoietic
cell transplantation (HCT). Several studies are available
comparing the outcome of HCT from an HLA-identical
sibling wherein peripheral blood is the source of HPC
with that following a BM harvest.6–12 Over the last years,
reduced intensity conditioning (RIC) has enriched the
treatment possibilities for elderly patients whose disease
could be cured with HCT. The frequencies of RIC HCT
have risen from less than 1% of all allogeneic HCT in 1998
to 34% in 2006.13 Consequently, an HLA-identical sibling
above the age of 60 years is expected to be encountered
more frequently. Paradoxically, only very limited data
exist regarding the impact of increasing donor age on
peripheral blood mobilization, quality of HPC harvested
and subsequent engraftment, and incidence of GVHD in
the recipient.
We retrospectively analyzed donors’ safety and the
impact of the age of matched related sibling donor
(MRD) on mobilization and collection of HPC, as well as
on subsequent engraftment and GVHD in 167 recipients of
HCT at the University of Leipzig.
Patients and methods
A total of 167 consecutive patients (72 (43%) females, and
95 (57%) males) who received HCT from a MRD at the
University of Leipzig from January 2000-January 2006
were retrospectively analyzed. HPC source was peripheral
blood in all patients. Informed consent was obtained from
both patients and donors.
Patient characteristics
Median age was 48 (range 18–74) years. Diagnoses were
acute leukemia (n¼ 67 (40%)), chronic leukemia (n¼ 37
(22%)), multiple myeloma (n¼ 24 (14%)), myelodysplastic
syndrome (n¼ 13 (8%)) and others (n¼ 26 (16%)). Con-
ventional conditioning with 12 gray TBI and CY 60mg/kg
body weight daily i.v. on days 1 and 2 (total dose 120mg/kg)
was given to 79 (47.3%) patients below 55 years of age.
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For older patients (n¼ 88 (52.7%)), RIC (fludarabine
30mg/m2 daily i.v. for 3 days and two gray TBI once,
followed by immunosuppression with CYA (through level
X200 ng/ml) and mycophenolate mofetil) was applied.
Donor characteristics
Siblings were 85 (51%) males and 82 (49%) females.
Median age was 47 (range 18–74) years, with 67 (40%)
donors (36 women, 31 men) being X50 years old including
34 donors (15 women, 19 men) being X60 years of age.
There was a similar gender distribution across all age
groups (P¼ 0.2). Of the 95 male patients, 44 (46.3%)
received a harvest from a female sibling. For the 72 female
patients, donors were 38 female and 34 male siblings.
Median body mass index of donors was 25.6 (range
18.3–40.8) kg/m2. Median body mass index in donors
who were X50–59 years was 27.3 kg/m2 compared with a
median of 25, and 26.6 kg/m2 in younger donors as well as
those X60 years of age, respectively (P¼ 0.02).
Donor work-up included detailed information about the
procedure and potential risks, obtaining a signed informed
consent, thorough clinical and laboratory evaluation,
an electrocardiogram, ultrasound examination of the
abdomen, chest X-ray and BM examination. A history of
hypertension was recorded in 92 (55%) of the donors, and
56 (33.5%) donors had a history of drug treatment. Further
relevant medical events, which did not preclude donation,
were captured 26 times (diabetes mellitus, n¼ 9; chronic
bronchitis, n¼ 6; history of venous thrombosis, n¼ 5; and
history of cardiac disease, n¼ 6). Table 1 shows patient and
donor characteristics.
Mobilization and harvest of HPC
Harvesting of HPC was made by leukapheresis after
treatment with filgrastim 5 mg/kg body weight, applied
subcutaneously twice daily starting on day ÿ4 of the
apheresis. In only 9 (5.4%) donors (o50 years, n¼ 6 and
X50 years, n¼ 3), peripheral veins were not considered
adequate and a central venous line was required for
apheresis. On the morning of the scheduled apheresis,
donor peripheral blood CD34þ cells were measured and
apheresis started, if the count was X1 107/L using the
COBE Spectra Apheresis System (CaridianBCT Inc.,
Lakewood, CO, USA). The volume of the harvest and
the counts for total mononuclear cells, T cells (CD3þ ),
CD34þ cells and natural killer (NK) (CD3ÿ/CD56þ )
cells were measured. If the target ofX3 106/ kg recipient’s
body weight (RBW) CD34þ cell count was not achieved by
one apheresis, the procedure was repeated the next day
after administration of two further injections of filgrastim
5 mg/kg body weight. The cells in all peripheral blood
samples and HPC products were sorted by flowcytometric-
activated cell sorting using the FACSCalibur Flow
Cytometer (BD Biosciences, San Jose, CA, USA) and
measured as previously described.14
Chimerism analyses in the recipient after RIC HCT
For patients receiving RIC HCT, donor chimerism in the
recipient was analyzed in unsorted BM cells, flow-sorted
T and CD34þ marrow cells on day 28 after HCT by
fluorescence in situ hybridization for the XY chromosome
in gender mismatched or PCR-based analysis of poly-
morphic microsatellite regions in gender-matched HCT.15
Safety assessment during mobilization and harvest of PBSC
All donors were mobilized as inpatients with daily clinical
and laboratory assessment during mobilization, during
and following apheresis. Laboratory assessment included a
blood count, liver function tests (alanine aminotrans-
ferase, aspartate aminotransferase, alkaline phosphates
and bilirubin), creatinine, lactate dehydrogenase, pro-
thrombin time, partial thromboplastin time and potassium.
In addition, all donors had a clinical and laboratory
evaluation 1 week, 1 month and 1 year after apheresis.
The National Cancer Institute Common Toxicity Criter-
ia Version 2.0 were used for assessment of hematological
and non-hematological side effects.
Statistical analysis
Univariate analyses were performed using the w2-test and
Fisher´s exact test for categorical and Mann–Whitney test
for continuous variables. Cox regression was used for
multivariate analyses. To analyze the impact of donors’ age
on mobilization and harvest of HPC, donors were
categorized in four groups: donors below 50 years of age
Table 1 Characteristics of patients and their HLA-identical donors
(n¼ 167)
Patients
Median age (years) 48 (18–74)
Gender No. (%)
Male 95 (57)
Female 72 (43)
Diagnosis
Acute leukemia 67 (40)
Chronic leukemia 37 (22)
MM 24 (14)
MDS 13 (8)
Others 26 (16)
Conditioning regimens
RIC 88 (52.7)
Conventional 79 (47.3)
Donors
Median age (years) 47 (18–74)
o 50 years 100 (59.9)
X50–59 years 33 (19.8)
X60 years 34 (20.3)
Gender
Male 85 (51)
Female 82 (49)
Patient/donor gender
Male/male 51 (30.5)
Male/female 44 (26.3)
Female/female 38 (22.8)
Female/male 34 (20.4)
History of hypertension in the donor
No 75 (45)
Yes 92 (55)
History of drug intake in the donor
No 111 (66.5)
Yes 56 (33.5)
Abbreviations: MDS¼myelodysplastic syndrome; MM¼multiple myeloma;
RIC¼ reduced intensity conditioning.
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(n¼ 100) vs the older donors (n¼ 67) and those below 60
years of age (n¼ 133) vs 60 years old and above (n¼ 34).
Statistical analysis was performed by SPSS 15.0 of
Windows software package (SPSS, Chicago, IL, USA).
Results
Mobilization and harvest of HPC
Mobilization was successful, with adequate harvests
collected in all donors after a median of one (range 1–3)
apheresis. In 148 (89%) donors, the target of X3 106/ kg
RBW CD34þ cell count was achieved by one apheresis
after a median of 22 (range 10–65) L of blood processed
during apheresis. Only five (3%) donors required three
sessions. With the exception of one donor where 2.8 106/ kg
RBW CD34þ cells were collected, all grafts contained
X3 106/kg RBW CD34þ cells. In univariate analysis,
donors X60 years tended to need more sessions (P¼ 0.07)
and a larger volume of blood processed during apheresis
(median 24L) compared with younger patients with a
median of 22L to yield the target CD34þ cell count
(P¼ 0.09) but this was not significant in multivariate
analysis (P¼ 0.9).
There was a strong negative association between the
age of the donor and peripheral blood CD34þ cell count
before apheresis in both univariate (Po0.0005) and
multivariate analyses (P¼ 0.01). Donors below 50 years
had significantly higher counts (median 7.5 (range 1–
25.2) 107/L) compared with older patients (median 4.7
(1–20.8) 107/L) (Figure 1) Similarly, grafts from donors
below 50 years contained significantly higher CD34þ cell
counts (median 9 (range 2.8–33) 106/kg RBW) compared
with older patients (median 5.9 (range 3.1–21) 106/ kg
RBW) (Po0.0005) (Figure 2) The lowest CD34þ cell
counts with a median of 5.9 (3.1–15) 106/kg RBW were
found in harvests from donors X60 years compared with
younger donors.
Irrespective of age, transplants from male donors
contained more CD34þ cells (median 8.6 106/ kg RBW)
compared with female siblings with a median of 6.4 106/kg
RBW (P¼ 0.004). The body mass index of the donor had no
influence on the CD34þ cell count (P¼ 0.6) nor on the
volume of blood processed during apheresis (P¼ 0.5).
On the other hand, significantly more NK cells were found
in harvests from donors X60 years (median 0.9 (range 0.3–
1.9) 106/kg RBW) compared with younger donors (median
0.6 (range 0.2–1.6) 106/kg RBW) (Figure 3)
Table 2 summarizes the impact of donors’ age on
mobilization and harvest of HPC.
Engraftment and donor chimerism in the recipient
As expected, in both uni- and multivariate analyses,
recipients of transplants from donors X50 years of age
were significantly older and were offered more often RIC
compared with recipients of grafts obtained from younger
donors (Po0.0005).
All patients engrafted with WBC count X1 109/L on
two consecutive days sustained platelet countsX50 109/L
without platelet transfusions observed after a median of
12 (range 0–37) and 12 (range 0–63) days after HCT
respectively. Although in univariate analysis, conventional
conditioning (P¼ 0.004), younger patient and donor ages
(P¼ 0.02), and lower CD34þ cell count in the harvest
(P¼ 0.01) were associated with a slower WBC recovery,
in multivariate analysis, only conventional conditioning
compared with RIC remained associated with a slower
WBC recovery (P¼ 0.005). Regarding platelet recovery,
p < 0.0005
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only a lower CD34þ cell count in the harvest was signifi-
cantly associated with a slower recovery in multivariate
analysis (P¼ 0.008).
NK-cell count in the graft had no impact on WBC
(P¼ 0.4) or platelet (P¼ 0.3) recovery. After RIC HCT,
median donor chimerism in unsorted marrow cells, CD3þ
and CD34þ cells on day 28 after HCT were 94 (range
22–100), 77 (range 10–100) and 99 (range 4–100) %,
respectively, and were not influenced by the number of NK
cells in the graft. Only in univariate analysis, donor age
X60 years was associated with a lower total and CD3þ
cell but not CD34þ cell donor chimerism in the recipient.
GVHD
Overall incidence of acute and chronic GVHD were 90/167
(53.9%) and 62/139 (44.6%), respectively (Table 3). Acute
GVHD was seen more often in patients below 50 years
compared with older patients (P¼ 0.007). This was mainly
because a significantly higher incidence of cutaneous GVHD
stages 1 and 2.
On the other hand, no correlation was found between
older age and chronic GVHD, although patientsX60 years
tended to suffer more often from chronic cutaneous GVHD
in comparison with younger patients (P¼ 0.02).
Interestingly, no association could be found between
donor age or NK-cell count in the transplant and the
incidence or severity of both acute and chronic GVHD.
Side effects of mobilization and harvest of HPC
In general, all donors, irrespective of age, tolerated
mobilization and apheresis well. There were no complica-
tions related to placement of central venous line in the nine
donors who required a central line for apheresis.
Table 2 Impact of donors’ age on mobilization and harvest of HPC (n¼ 167)
Parameter o60 years vs X60 years o50 years vs X50 years
Uni (P-value) Multi (P-value) Uni (P-value) Multi (P-value)
No. of apheresis sessions, median 1 (range 1–3) 0.07 NS NS
Filgrastim dose required for mobilization NS NS
Peripheral CD34+ cells before apheresis, median 6.3 (range 1–25.2) 107/L 0.001 NS o0.0005 0.01
Hb, median (range) g per 100mL
Before mobilization, 14.3 (11–17.6) NS NS
Before apheresis14, (9.5 –16.8) NS NS
After apheresis, 13 (8.1–15.8) NS NS
WBC, median (range) 109/L
Before mobilization, 6.7 (2.8–14.5) NS NS
Before apheresis, 50.4 (22.5–94.5) NS 0.04 0.08
After apheresis, 40.9 (10.3–82.8) NS 0.009 NS
Plts, median (range) 109/L
Before mobilization, 246 (127–467) NS NS
Before apheresis, 225 (85–459) NS 0.09 NS
After apheresis, 94 (22–275 NS 0.02 NS
CTC toxicity Xgrade II NS NS
Graft, median (range)
Vol, 295 (83–1499) ml NS NS
CD34+ cells, 7.2 (2.8–33) 106/kg 0.003 0.006 o0.0005 NS
CD3+ cells, 3.8 (0.8–21.8)  108/kg NS NS
NK cells, 0.7 (0.2–1.9) 106/kg 0.003 0.001 0.01 0.07
Non-hematological CTC toxicity X grade II NS NS
AP 0.005 0.07 0.04 NS
PPT NS NS
Potassium NS NS
Abbreviations: AP¼ alkaline phosphatase; CTC¼ the National Cancer Institute Common Toxicity Criteria; Multi¼multivariate analyses; NK
cells¼ natural killer cells; PTT¼ partial thromboplastin time; Uni¼ univariate analyses.
p = 0.003
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No differences were noted in median Hb, WBC and
platelet counts before mobilization in regard to age. On the
other hand, donors X50 years of age tended to have
significant lower WBC counts before apheresis compared
with younger patients.
Although donorsX50 years of age tended to have lower
platelet counts after apheresis in univariate analysis
(P¼ 0.02), this was not significant in multivariate analysis
(P¼ 0.2). The degree of thrombocytopenia under apheresis
and platelet recovery thereafter was not influenced by age.
No bleeding episode was encountered in the entire cohort
(Table 2).
Under mobilization and apheresis, 129 (77%) donors
experienced no symptoms. Bone pain was reported in 38
(23%) donors, which was greater than grade 2 in seven
(4.2%) donors.
No greater than grade 2 alanine aminotransferase,
aspartate aminotransferase, bilirubin, creatinine, fibrino-
gen, lactate dehydrogenase or prothrombin time toxicities
were detected. Reversible alkaline phosphate elevation was
noted in 106 (63.5%) (grade 1 in 49, grade 2 in 46, and
grade 3 in 11) donors.
After apheresis, a prolonged partial thromboplastin time
was seen in 56 (33.5%) (grade 1 in 45, grade 2 in 8, grade 3
in 1 and grade IV in 2) donors. Partial thromboplastin time
normalized spontaneously in all donors within 4–6 h after
apheresis. Also hypokalemia successfully managed with
oral potassium was observed in 74 (44.3%) (grade 1 in 35,
grade 2 in 35 and grade 3 in 4) donors. Elderly donors did
not witness more toxicities compared with younger donors.
Regarding alkaline phosphate, age o60 years was clearly
associated with more alkaline phosphate elevations in both
uni- and multivariate analyses.
Table 2 summarizes the impact of the age of the donor
on hematological and non-hematological toxicities under
mobilization and harvest of HPC.
Second mobilization and harvest of HPC
From the whole cohort of donors, 24 (13.6%). underwent a
second mobilization and collection of HPC after a median
of 256 (range 89–1589) days following the first donation
because of relapse of the underlying disease in the recipient.
Median age of patients and donors were 51 (range 18–68)
and 46 (21–68) years, respectively. Eight (33.3%) donors
were X50 years old. Similar to the first apheresis, the
second donation was successful and without significant side
effects in all donors irrespective of age.
Discussion
Granulocyte colony-stimulating factor-mobilized periph-
eral blood is feasible, convenient and considered the
predominant source of stem cells.1–5 It is inevitable that
the increasing frequency of patients who are offered RIC
HCT, mainly because of advanced age, would be accom-
panied by an increasing number of elderly matched sibling
donors. Only very limited data exist regarding the impact of
an increasing donor age on the feasibility and quality of
mobilization and harvest of HPC, as well as subsequent
engraftment and GVHD in the recipient. In a recent
publication, Tempescul et al. showed that in the setting
of autologous HCT, patients older than 65 years with
myeloma or lymphoma could also undergo HPC harvests
similar to younger patients, with the majority of patients
only needing one apheresis (71%).16 On the other hand, an
inverse correlation between the pre-apheresis CD34þ cell
count and age in related donors stimulated with lenogras-
tim has been published.17 Our data demonstrate clearly that
increasing age of identical siblings deemed fit for donation
does not preclude successful mobilization and collection of
HPC. Although donors younger than 50 years mobilized
more efficiently as reflected in a higher median peripheral
blood CD34þ cell count before collection and a higher
median CD34þ cell count in the harvests compared
with older donors, nevertheless transplants from all donors,
Table 3 Acute and chronic GVHD
Parameter Acute GVHD,
N (%)
Chronic
GVHD,
N (%)
Incidence 90/167 (53.9) 62/139 (44.6)
Severity
Grade I 41/90 (45.6) Limited 28/62 (45.2)
Grade II 15/90 (16.7) Extensive 34/62 (54.8)
Grade III 27/90 (30)
Grade IV 7/90 (7.7)
Organ involveda
Skin 81/90 (90) 35/62 (56.5)
Stage p2 58/81 (71.6)
Stage X3 23/81 (28.4)
Liver 18/90 (20) 23/62 (37)
Gut 36/90 (40) 10/62 (16.1)
Others 22/62 (35.5)
Age of patients (years)
o50 58/91 (63.7) 37/79 (46.8)
Skin
Stage p2 38/91 (41.8)
Stage X3 13/91 (14.3)
50–59 15/37 (40.5) 9/31 (29)
Skin
Stage p2 9/37 (24.3)
Stage X3 6/37 (16.2)
X60 17/39 (43.6) 16/31 (51.6)
Skin
Stage p2 11/39 (28.2)
Stage X3 4/39 (10.3)
o50 vs X50 P¼ 0.007 P¼ 0.1
Female donor to
male patient
(n¼ 34) vs
the rest (133)
P¼ 0.9 P¼ 0.2
Age of donors
(years)o50 vsX50
P¼ 0.5 P¼ 0.6
NK-cell count
in the harvest
P¼ 0.95 P¼ 0.8
Abbreviation: NK cells¼natural killer cells.
aPatients had one or more organ involvement.
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irrespective of age, contained sufficient HPC and
T lymphocytes required for successful engraftment.
An interesting observation was the strong positive
correlation of NK-cell counts in the harvests and the age
of the donor. The older the donor, the more NK cells were
collected in our cohort. NK cells, the first lymphocyte
subset to reconstitute the peripheral blood after allogeneic
HCT,18–20 have been implicated in the suppression of
GVHD, the promotion of engraftment and the mediation
of a GVL effect.21–28 Mediators of the inhibitory signals for
NK-cell activity include the inhibitory killer Ig-like
receptors (KIRs), many of which are known to have
differential ligand specificities for HLA class I molecules.
Upon interaction with target cells lacking HLA ligand,
inhibitory KIR-expressing NK cells may have a lowered
threshold for activation, particularly if target cells express
additional activating NK receptor ligands.21,22 When
exerted in the donor-vs-recipient direction, NK-cell allor-
eactivity emerged as a crucial factor in improving outcome
of haploidentical transplantation, with alloreactive clones
detectable in vivo in recipients for up to 1 year after
transplant.29 Also, in HLA-identical sibling transplanta-
tions, Hsu et al. demonstrated by analyzing donor KIR
genotype with HLA genotype that 62.9% of the patients
lacked an HLA ligand for donor-inhibitory KIR. Their
data suggest that the absence of class I ligand in the
recipient for donor-inhibitory KIR can contribute to
improved outcome for patients with AML and MDS.30
In our study, higher NK-cell count in the transplant was
not associated with a higher incidence of GVHD or with
delayed engraftment. Nevertheless, the influence of the
number of transfused NK cells with or without NK-cell
alloreactivity on outcome after allogeneic HCT is an
interesting and challenging aspect to be addressed in future
clinical studies.
Another positive observation was the fact that advanced
donor age was not associated with an increased incidence of
acute and chronic GVHD in the recipient.
Also, there was no increased incidence in hematological or
non-hematological toxicities with increasing donor age
during mobilization, collection of HPC and no serious
adverse events were reported in the first year after donation.
Nevertheless, a few points need to be addressed.
Although the risk for the donor is generally considered
minimal, there is a small but definite risk of serious adverse
events and fatalities. Additionally, experimental data and
observational reports raised concern about an elevated risk
of hematologic malignancies after granulocyte colony-
stimulating factors administration.31,32
In a recent survey conducted by the European Group for
Blood and Marrow Transplantation (EBMT) including
23 254 donors of peripheral HPC four fatalities (incidence
0.98 per 10 000 donations; 95% confidence interval
0.32–2.29), 25 severe adverse events (10.76/10,000; 95%
confidence interval 6.97–15.85) and 12 hematologic malig-
nancies were reported. The calculated incidence of hema-
tologic malignancies of 1.20 per 10 000 person–years of
follow-up did not exceed the expected incidence in an age-
and sex-adjusted general population.5
In our cohort, the median age of donors was 47 years,
with 40% of donors being X50 years old compared with a
median of 43.7 years for related donors of peripheral HPC
in the EBMT survey. It is expected that with the increasing
age of the recipients of HCT, the number of older family
donors with comorbidities will continue to increase.
Further, true incidences of long-term complications
might be higher as reported because lack of standardized
donor follow-up and underreporting of data from donors
whose recipients died.
So, donors must be informed about the potential risks of
donation, systematic follow-up of donors established and
serious adverse captured in prospective studies.
Implementing the Joint Accreditation Committee-ISCT
& EBMT (JACIE), accreditation standards have led to
significant improvements in different aspects of transplant
programs including donor and collection issues.33
In conclusion, an increasing age of matched related
siblings does not preclude successful mobilization and
collection of HPC, and seems to have no negative impact
on both subsequent engraftment and the incidence of
acute as well as chronic GVHD in the recipient. For the
first time, we describe a higher NK-cell count encountered
in grafts from elderly donors. The age of the donor as a
possible donor-related factor possibly influencing outcome
after HCT needs to be further evaluated. In the era of
older family donors with possible comorbidities, long-term
safety after donation becomes even more important than
ever before.
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 Hematopoeitic cell transplantation (HCT) offers a chance for cure or long-term 
remission and is an established treatment option for different malignant and non-
malignant hematologic and non-hematologic diseases.
 In HCT, hematopoietic progenitor cells (HPCs) with their capacity to divide 
indefinitely, to self-renew and to generate a functional progeny of highly 
specialized cells are given to the patient after inducing myeloablation and/or 
immunoablation with chemotherapy + irradiation. 
 Nowadays, HPCs could be procured from the bone marrow, peripheral blood and 
umbilical cord blood. Granulocyte-colony stimulating factor (G-CSF) mobilized 
stem cells from the peripheral blood (PBSCs) collected via leukapheresis are the 
most common source of HPCs worldwide. This collection is considered to be 
convenient and the risk is considered minimal. 
 In autologous HCT, the patient's own HPCs are re-infused after inducing bone 
marrow ablation to eradicate the diseased cell population. It is associated with a 
low treatment-related mortality (TRM). However, this low TRM is counterbalanced 
by a high relapse rate which limits its utility in some disorders such as leukemia. 
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 In allogeneic HCT, HPCs from another individual "the donor" are given to the 
patient "the recipient" after myeloablative preparation "the conditioning regimen" to 
eradicate the disease clone. The toxicity of myeloablation limited the availability of 
this form of HCT to younger patients. 
 Allogeneic HCT is the only transplant procedure in which the transplanted cells 
must accept the body of the recipient rather than the body accepting the new cells. 
The major barrier to allogeneic HCT is the human leukocyte antigen (HLA) 
system. If major histocompatibility antigens of the donor are incompatible with 
those of the recipient, vigorous T-cell responses occur with serious and even 
lethal immune reactions in the recipient, known as the graft versus host disease 
(GVHD). 
 HLA typing is mandatory for the identification of a suitable matched donor. The 
ideal donor is an HLA genotypically matched related sibling donor (MRD). High 
resolution HLA typing allows the identification of suitable matched unrelated 
donors for patients with no MRD. 
 After allogeneic HCT, malignant stem cells could additionally be eliminated by the 
potent graft versus tumor (GVT) or graft versus leukemia (GVL) effect which is 
mediated by the immunologically active donor T-cells that recognize disease 
specific antigens in the recipient. Thus, allogeneic HCT is an immunotherapy with 
a potent curative potential. 
 In addition to the HLA system, minor histocompatibility antigens and natural killer 
(NK)-cells do play a substantial role in the immunogentics of allogeneic HCT. 
These factors could initiate and/or augement the GVL effect and GVHD even in 
"perfect HLA matches". 
 The appreciation of the immunologic mediated GVL effect led to the development 
of the primarily immunosuppressive rather than myeloablative reduced-intensity 
conditioning (RIC) regimens. 
 The low toxicity of RIC allowed the extension of the curative potential of allogeneic 
HCT to older patients and to recipients with comorbidities for whom myeloablative 
conditioning.was not possible. 
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 GVHD which could be acute and/or chronic remains a serious complication and is 
the major cause of TRM and morbidity after allogeneic HCT including RIC-HCT. 
 The introduction of RIC raises new challenges as the increasing age of patients is 
inevitably accompanied by a comparable increase in the age and/or comorbidities 
of sibling donors. Consequently, safety issuses regarding G-CSF mobilization of 
HPCs and leukapheresis of PBSCs might attain new dimensions. Data to potential 
risks in elderly sibling donors are actually lacking. Likewise, data to the quality of 
harvests obtained from elderly donors in terms of the number of stem cells 
(CD34+-cells) and NK-cells are scarce. It is also unknown whether PBSCs 
obtained from donors above 50 or even 60 years of age would influence 
engraftment or the incidence of GVHD in the recipient. 
 These open questions were explored in a large study including 167 patients 
conducted retrospectively in the department of Hematology and Oncology at the 
University Hospital of Leipzig. 
  Patients with a median age of 48 (range 1874) years who received an allogeneic 
HCT from a MRD were sudied. Allogeneic HCT was performed because of 
leukemia in 62% of patients. Conventional conditioning was given to 79 (47.3%) 
patients below 55 years of age while RIC was offered to the remaining 88 (52.7%) 
patients because of advanced age. 
 The median age of sibling donors was 47 (range 1874) years, with 67 (40%) 
donors being > 50 years including 34 donors > 60 years of age. Work-up for 
eligibility for donation was conducted according to institutional guidelines which 
are based on the Joint Accreditation Committee-ISCT and EBMT (JACIE) 
accreditation standards. 
 Donors were mobilized with G-CSF and the peripheral blood CD34+ -cell counts 
were measured prior to leukapheresis. If the count was > 1x107/L, harvesting 
using the COBE Spectra Apheresis System (CaridianBCT Inc., Lakewood, CO, 
USA) was started. The target was the procurment of > 3x106/ kg recipients body 
weight (RBW) CD34+ -cells. 
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 Statistically, donors were categorized into four groups: donors below 50 years 
(n=100) versus older donors (n=67) and those below 60 years of age (n=133) 
versus 60 years and above (n=34). Statistical analysis was performed by SPSS 
15.0 of Windows software package (SPSS, Chicago, IL, USA). 
 Irrespective of age, mobilization and leukapheresis of PBSCs was well tolerated. 
There were no short-term serious clinical or laboratory adverse events in the 
entire cohort. 
 Irrespective of age, the target stem cell count of > 3x106/ kg RBW was achieved in 
all but one donor. There was a strong inverse association between the age of the 
donor and peripheral blood CD34+ -cell count prior to leukapheresis in both uni- 
(p=0.0005) and multivariate analyses (p=0.01). Donors < 50 years had higher 
CD34+ -cell counts with a median of 7.5 x107/L compared to a median of 4.7 x107/L  
in older donors. Likewise, grafts from donors < 50 years contained significantly 
more CD34+ -cells with a median of 9 x106 / kg RBW compared to harvests 
obtained from older donors which contained a median of 5.9 x106 / kg RBW 
(p<0.0005).  
 Significantly more NK-cells were found in harvests from donors > 60 years with a 
median of 0.9 x106 / kg RBW  compared to grafts from younger donors (median 
0.6 x106 / kg RBW (p=0.003). 
 After HCT, all recipients engrafted after a median of 12 days. In multivariate 
analysis, myeloablative conditionig and a lower CD34+ -cells count but not donor's 
age were associated with a slower white blood cell (p=0.005), and platelet counts 
recovery (p=0.008) respectively. 
 The incidence of acute and chronic GVHD in the recipients were 53.9% and 
44.6%, respectively. Acute cutaneous GVHD was seen more often in patients < 
50 years (p=0.007) while chronic cutaneous GVHD was more frequent in patients 
> 60 years (p=0.02). There was no correlation between the age of the donor and 
other organ involvement by chronic GVHD in the recipient.  
 NK-cells, the first lymphocyte subset to reconstitute the peripheral blood after 
allogeneic HCT, have been implicated in the suppression of GVHD, the promotion 
of engraftment and the mediation of a GVL effect. This NK-cell alloreactivity has 
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been shown to be due to the absence of the class I ligand (which is the case in 
63% of recipients of grafts from MRD) for the donor-inhibitory killer Ig-like 
receptors of NK-cells and to improve outcome after HCT. 
 The impact of the higher NK-cell count in grafts from elderly donors observed in 
this trial on outcome after allogeneic HCT is yet unknown and warrants further 
studies. 
 For the first time, we showd that age even beyond 60 years does not preclude 
successful mobilization and collection of PBSCs from sibling donors, does not 
jeopardize the short-term safety of the donor, and is not associated with 
deleterious sequels for the recipient in terms of engraftment or GVHD. 
 The true incidence of potential long-term risks to donors might be higher than 
reported in the literature because of lack of standardized donor follow-up. 
Systematic follow-up of donors need to be established. 
 Short- and long-term outcome after allogeneic HCT is the end-result of a complex 
interaction of disease-, patient-, and treatment-related prognostic variables. 
Donor-specific aspects might additionally impact survival, the relapse incidence, 
as well as TRM and morbidity in the recipient after allogeneic HCT and must be 
further elucidated. 
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